RGNT net incomeFY2025-$13.65M
RGNT net income was -$13.65M for fiscal 2025 (ended Dec 31, 2025), compared with $4.80M in fiscal 2024.
Regentis Biomaterials Ltd. (RGNT) financials
For fiscal 2025 (ended Dec 31, 2025), Regentis Biomaterials Ltd. reported -$13.65M of net income.
- Net income, FY2025
- -$13.65M
- EPS, diluted, FY2025
- -$24.16
- Cash
- $7.38M
- Market cap
- $9.3M
FY2023FY2025
RGNT revenue and earnings growth
RGNT EPSFY2025-$24.16
RGNT diluted EPS was -$24.16 for fiscal 2025 (ended Dec 31, 2025).
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Selling, general and admin | $6.64M | $712.0K | $1.13M |
| Operating income | -$6.97M | $932.0K | -$1.93M |
| Pre-tax income | $13.65M | -$4.80M | $4.13M |
| Net income | -$13.65M | $4.80M | -$4.13M |
| EPS, basic | -$24.16 | $1.72 | -$24.09 |
| EPS, diluted | -$24.16 | $1.72 | -$24.09 |
| Diluted shares | 566,744 | 2.8M | 173,508 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $7.38M | - | - |
| Total assets | $7.62M | $482.0K | - |
| Current liabilities | $2.87M | $6.49M | - |
| Short-term debt | $1.20M | $573.0K | $210.0K |
| Total liabilities | $2.87M | $6.49M | - |
| Shareholders' equity | $4.74M | -$41.10M | -$45.91M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -$1.38M | -$641.0K | -$1.22M |
| Financing cash flow | $8.52M | $525.0K | $325.0K |
| Stock-based compensation | $7.04M | - | - |
Key ratios
Source: XBRL data Regentis Biomaterials Ltd. files with the SEC, latest filing dated Feb 27, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
RGNT peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| RGNT | - | - | -$13.65M | - | $9.3M |
| ISRG | $11.58B | +20.5% | $2.96B | 25.5% | $156.00B |
| EW | $6.67B | +13.4% | $1.02B | 15.3% | $59.81B |
| STE | $6.17B | +8.1% | $826.90M | 13.4% | $24.97B |
| ZBH | $8.57B | +7.0% | $767.30M | 9.0% | $20.31B |
| MAS | $7.67B | +0.9% | $926.00M | 12.1% | $16.35B |
| SNN | $6.16B | +6.1% | $625.00M | 10.1% | $12.94B |
| ALGN | $4.16B | +4.4% | $491.87M | 11.8% | $12.28B |
| AIT | $5.06B | +8.5% | $424.12M | 8.4% | $10.92B |
RGNT FAQ
5 questionsIs RGNT profitable?
No. Regentis Biomaterials Ltd. reported a net loss of $13.65M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does RGNT have?
Regentis Biomaterials Ltd. reported $7.38M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is RGNT earnings per share?
Diluted earnings per share were -$24.16 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did RGNT last report financial results?
The latest statements here come from Regentis Biomaterials Ltd.'s 20-F/A filed on Feb 27, 2026, covering the period ended Dec 31, 2025.Where does this RGNT financial data come from?
Quantisnow builds these statements from the structured XBRL data Regentis Biomaterials Ltd. files with the SEC. It is provided for information only and is not investment advice.